NEOGAP acquires TCER Oncology AB, strengthening its position in personalised immunotherapy
“We are delighted to acquire the remaining shares in TCER Oncology and extend a warm welcome to Rolf Kiessling and Stina Wickström as valued shareholders in NEOGAP. This acquisition marks an important milestone, fortifying our standing in personalised immunotherapy. It allows us to expand our patent portfolio and pipeline of potential drug candidates while further developing our innovations in the field. We look forward to continuing to drive progress and deliver groundbreaking scientific breakthroughs in cancer treatment,” says Samuel Svensson, CEO of NEOGAP.
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines